rTMS Treatment in Patients With General Anxiety Disorder

Inclusion Criteria

• •signed patient informed consent;
• •primary GAD diagnosis;
• •HARS \>=15;
• •male/female 18-65 years;
• •without GAD pharmacotherapy at least last 2 weeks or if they are taking GAD medication it must be stable for at least 6 weeks prior to the start of the study and not be changed during the 6 weeks of the study treatment phase.
• •Individual or group supportive psychotherapy may continue during the study but will not be allowed to start new psychotherapy during the 6 weeks of the study treatment phase.